Oxybutynin
- Generic Name
- Oxybutynin
- Brand Names
- Ditropan, Gelnique, Kentera, Oxytrol, Kentera (previously Oxybutynin Nicobrand)
- Drug Type
- Small Molecule
- Chemical Formula
- C22H31NO3
- CAS Number
- 5633-20-5
- Unique Ingredient Identifier
- K9P6MC7092
- Background
Overactive bladder (OAB) is a common condition negatively impacting the lives of millions of patients worldwide. Due to its urinary symptoms that include nocturia, urgency, and frequency, this condition causes social embarrassment and a poor quality of life.
...
- Indication
Oxybutynin is indicated for the symptomatic treatment of overactive bladder, which causes urge urinary incontinence and frequency, and urgency. Oxybutynin may also be used for children aged 6 and above for the symptomatic management of detrusor muscle overactivity which has been found to be related to a neurological condition. Spina bifida is an example of a...
- Associated Conditions
- Bladder Spasms, Detrusor Hyperreflexia, Overactive Bladder Syndrome (OABS)
- Associated Therapies
- -
Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence
- Conditions
- Interventions
- First Posted Date
- 2009-05-27
- Last Posted Date
- 2014-07-02
- Lead Sponsor
- Antares Pharma Inc.
- Target Recruit Count
- 626
- Registration Number
- NCT00909181
A Study of Oxybutynin for the Treatment of Urge Urinary Incontinence
- First Posted Date
- 2008-09-09
- Last Posted Date
- 2009-10-15
- Lead Sponsor
- FemmePharma Global Healthcare, Inc.
- Target Recruit Count
- 45
- Registration Number
- NCT00749632
- Locations
- 🇺🇸
SNBL Clinical Pharmacology Center, Baltimore, Maryland, United States
🇺🇸Advanced Biomedical Research, Hackensack, New Jersey, United States
Efficacy and Safety of OROS Oybutynin and TTS Oxybutynin in Middle-Aged and Elderly Women With Urinary Incontinence
- Conditions
- First Posted Date
- 2006-03-20
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- Alza Corporation, DE, USA
- Target Recruit Count
- 176
- Registration Number
- NCT00304499
Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive Bladder
- Conditions
- First Posted Date
- 2006-02-20
- Last Posted Date
- 2010-12-09
- Lead Sponsor
- Alza Corporation, DE, USA
- Target Recruit Count
- 790
- Registration Number
- NCT00293839
Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2012-02-09
- Lead Sponsor
- Watson Pharmaceuticals
- Target Recruit Count
- 57
- Registration Number
- NCT00224016
- Locations
- 🇺🇸
Watson Investigational Site, Salt Lake City, Utah, United States
Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2008-01-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 150
- Registration Number
- NCT00170768
- Locations
- 🇺🇸
Washington Neuropsychological Institute LLC Georgetown, Washington, District of Columbia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.